000 | 01863 a2200553 4500 | ||
---|---|---|---|
005 | 20250517093825.0 | ||
264 | 0 | _c20171106 | |
008 | 201711s 0 0 eng d | ||
022 | _a1872-9096 | ||
024 | 7 |
_a10.1016/j.antiviral.2016.05.002 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aWillemse, S B | |
245 | 0 | 0 |
_aIntrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir. _h[electronic resource] |
260 |
_bAntiviral research _c07 2016 |
||
300 |
_a148-55 p. _bdigital |
||
500 | _aPublication Type: Journal Article | ||
650 | 0 | 4 |
_aAdenine _xanalogs & derivatives |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAlanine Transaminase _xblood |
650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
650 | 0 | 4 |
_aBiomarkers _xanalysis |
650 | 0 | 4 | _aBiopsy |
650 | 0 | 4 |
_aChemokine CXCL10 _xblood |
650 | 0 | 4 |
_aDNA, Viral _xblood |
650 | 0 | 4 | _aDrug Therapy, Combination |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 |
_aHepatitis B e Antigens _xblood |
650 | 0 | 4 |
_aHepatitis B, Chronic _xdrug therapy |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aInterferon-alpha _xtherapeutic use |
650 | 0 | 4 |
_aLiver _ximmunology |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aOrganophosphonates _xtherapeutic use |
650 | 0 | 4 |
_aPolyethylene Glycols _xtherapeutic use |
650 | 0 | 4 | _aProspective Studies |
650 | 0 | 4 | _aRNA, Messenger |
650 | 0 | 4 |
_aRecombinant Proteins _xtherapeutic use |
650 | 0 | 4 | _aTreatment Outcome |
700 | 1 | _aJansen, L | |
700 | 1 | _ade Niet, A | |
700 | 1 | _aSinnige, M J | |
700 | 1 | _aTakkenberg, R B | |
700 | 1 | _aVerheij, J | |
700 | 1 | _aKootstra, N A | |
700 | 1 | _aReesink, H W | |
773 | 0 |
_tAntiviral research _gvol. 131 _gp. 148-55 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.antiviral.2016.05.002 _zAvailable from publisher's website |
999 |
_c25997353 _d25997353 |